Merck Press Releases - EIN Presswire - Press Release Distribution Service

Published on May 23, 2013 - 22:03 GMT

Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck’s investigational adenosine A2A receptor antagonist for the treatment …

Distribution channels: Companies

Published on May 22, 2013 - 23:21 GMT

Merck Statement on FDA Advisory Committee Meeting for Suvorexant

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of …

Distribution channels: Companies

Published on May 21, 2013 - 21:33 GMT

Merck Announces $5 Billion Accelerated Share Repurchase

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has entered into an accelerated share repurchase agreement (ASR) with Goldman, Sachs Co. to repurchase $5 billion of …

Distribution channels: Companies

Published on May 17, 2013 - 21:52 GMT

Merck to Present at the UBS Global Healthcare Conference

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Peter N. Kellogg, executive vice president and chief financial officer, Merck, is scheduled to present at the UBS Global …

Distribution channels: Companies

Published on May 17, 2013 - 13:48 GMT

Global Health, Development and Business Leaders Announce New Innovative Financing Partnership to Deliver Essential Health Supplies ...

NEW YORK--(BUSINESS WIRE)--Today, leading global health and development experts from the public and private sectors are joining forces at the 2013 GBCHealth Conference to announce a new partnership that will leverage private sector funding to speed up …

Distribution channels: Companies

Published on May 15, 2013 - 23:15 GMT

Merck Prices $ 6.5 Billion Debt Offering

Wednesday, May 15, 2013 6:29 pm EDT WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck Co., Inc. priced today a $6.5 billion public offering of senior unsecured notes. The notes include: $1,000 million of 0.70% notes due May 2016 $500 million of floating …

Distribution channels: Companies

Published on May 14, 2013 - 21:41 GMT

Merck for Mothers Launches Initiative in India to Reduce the Number of Women Dying During Pregnancy and Childbirth

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Merck for Mothers has launched its global initiative for helping reduce maternal mortality in India. It is partnering with three leading non-governmental …

Distribution channels: Companies

Published on May 14, 2013 - 15:11 GMT

Merck to Present at the Bank of America/Merrill Lynch 2013 Healthcare Conference

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Frank Clyburn, president, Primary Care and Women's Health, Merck, is scheduled to present at the Bank of America/ …

Distribution channels: Companies

Published on May 9, 2013 - 11:25 GMT

GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], Merck’s HPV Vaccine, Available to ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the company has been awarded a significant portion of the UNICEF human papillomavirus (HPV) vaccine tender, and will …

Distribution channels: Companies

Published on May 8, 2013 - 13:40 GMT

Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Biologics License Application (BLA) for its investigational ragweed pollen (Ambrosia artemisiifolia) sublingual …

Distribution channels: Companies

Published on May 7, 2013 - 17:28 GMT

FDA Approves Merck’s LIPTRUZET™ (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LIPTRUZET™(ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein (LDL) …

Distribution channels: Companies

Published on May 7, 2013 - 15:55 GMT

Merck and Celebrity Chef Art Smith “Cook Up a Recipe” for Better Type 2 Diabetes Management

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced its partnership with celebrity chef Art Smith onTaking Diabetes to Heart, an educational program to help people living with type 2 diabetes better manage the disease. …

Distribution channels: Companies

Published on May 1, 2013 - 12:17 GMT

Merck Announces New $15 Billion Share Repurchase Program

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its board of directors has authorized additional purchases of up to $15 billion of Merck’s common stock for its treasury. …

Distribution channels: Companies

Published on May 1, 2013 - 12:16 GMT

Merck Announces First-Quarter 2013 Financial Results

2013 First-Quarter Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.52 Worldwide Sales were $10.7 Billion, a Decrease of 9 Percent Primarily as a Result of Patent Expiries, and Including a 2 Percent Unfavorable Impact from Foreign Exchange …

Distribution channels: Companies

Published on April 29, 2013 - 21:31 GMT

Merck Wins FOSAMAX® (alendronate sodium) Federal Bellwether Trial Involving Atypical Femur Fracture Claims

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today said a jury found in its favor in the Glynn v. Merck case in the U.S. District Court for the District of New Jersey. In the case, the plaintiff …

Distribution channels: Companies

Published on April 29, 2013 - 11:59 GMT

Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an ...

WHITEHOUSE STATION, N.J. NEW YORK--(BUSINESS WIRE)--Merck Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada (“Merck”), and Pfizer Inc. (NYSE:PFE) today announced that they have entered into a worldwide (except Japan) collaboration …

Distribution channels: Companies

Published on April 24, 2013 - 11:45 GMT

Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the …

Distribution channels: Companies

Published on April 23, 2013 - 10:30 GMT

Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating …

Distribution channels: Companies

Published on April 22, 2013 - 12:42 GMT

Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination …

Distribution channels: Companies

Published on April 16, 2013 - 12:57 GMT

Merck Opens New Manufacturing Facility in Hangzhou, China

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the opening of its new pharmaceutical manufacturing facility in Hangzhou, China. The facility, located in the Hangzhou Economic and Technology Area (HEDA), will package …

Distribution channels: Companies